<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="93949">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01730755</url>
  </required_header>
  <id_info>
    <org_study_id>I-RUX-12-03</org_study_id>
    <nct_id>NCT01730755</nct_id>
  </id_info>
  <brief_title>Ruxolitinib for Chuvash Polycythemia</brief_title>
  <official_title>Ruxolitinib for Chuvash Polycythemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chuvash polycythemia (CP) is a rare form of congenital polycythemia caused by mutations in
      the VHL gene. Currently, there are no therapies that have proven effective for CP. Recent
      studies have demonstrated that VHL regulates the activity of JAK2. In mouse models,
      inhibition of JAK2 reverses the CP phenotype. Therefore, the investigators hypothesize that
      JAK2 inhibition may have significant clinical benefits for CP patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study involvement will last for 48 weeks. There will be approximately 11 visits through week
      48. Visits may take up to 2-3 hours to complete and occur every 4 weeks for the first 24
      weeks, then every 12 weeks until week 48.

      During each study visit, any or all of the following procedures may occur:

        -  List current medications and participant general health

        -  Obtain blood pressure, body weight, body temperature, respiratory rate and heart rate

        -  Measure Spleen by examination

        -  Obtain an abdominal MRI to evaluate spleen and any pre-existing or new blood clots

        -  Obtain blood samples for safety tests and to monitor kidney/liver function.

        -  Questionnaires for participant to complete regarding symptoms related to disease.

        -  Ruxolitinib dosing may be increased after 4 weeks if needed. The dose of the
           ruxolitinib may be reduced related to side effects.
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <phase>N/A</phase>
  <study_type>Expanded Access</study_type>
  <study_design>N/A</study_design>
  <condition>Chuvash Polycythemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib</intervention_name>
    <description>Ruxolitinib 10 mg tablets twice daily</description>
    <other_name>Jakafi</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Chuvash polycythemia

        Exclusion Criteria:

          -  Unable to comprehend or unwilling to sign an informed consent form.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Stephen Oh, MD, PhD</last_name>
    <phone>314-362-8846</phone>
    <email>stoh@dom.wustl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Karyn Gordon, BSN</last_name>
      <phone>314-362-0156</phone>
      <email>kgordon@dom.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Stephen Oh, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>November 15, 2012</lastchanged_date>
  <firstreceived_date>November 7, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Polycythemia</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Polycythemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
